{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:21:09Z","timestamp":1780467669464,"version":"3.54.1"},"reference-count":177,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40263-025-01248-7","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:55:48Z","timestamp":1764320148000},"page":"133-164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010\u20132025): 15\u00a0Years of Progress (or Lack Thereof)"],"prefix":"10.1007","volume":"40","author":[{"given":"Drew","family":"Hirsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jace","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasim","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Ngor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Dugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando Sceptre","family":"Ganasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla","family":"Truman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itai","family":"Danovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-4756","authenticated-orcid":false,"given":"Waguih William","family":"IsHak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hedrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"1248_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, American Psychiatric Association, editors. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C: American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"6","key":"1248_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/YCO.0b013e328365a24f","volume":"26","author":"FRE Smink","year":"2013","unstructured":"Smink FRE, Van Hoeken D, Hoek HW. Epidemiology, course, and outcome of eating disorders. Curr Opin Psychiatry. 2013;26(6):543\u20138. https:\/\/doi.org\/10.1097\/YCO.0b013e328365a24f.","journal-title":"Curr Opin Psychiatry"},{"key":"1248_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/eat.23954","volume":"56","author":"EE Fitzsimmons\u2010Craft","year":"2023","unstructured":"Fitzsimmons\u2010Craft EE. Decreasing the public health burden of eating disorders: commentary Schleider et al. (2023). Int J Eat Disord. 2023;56:871\u20134. https:\/\/doi.org\/10.1002\/eat.23954.","journal-title":"Int J Eat Disord"},{"key":"1248_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40337-022-00597-8","volume":"10","author":"E Bryant","year":"2022","unstructured":"Bryant E, Spielman K, Le A, Marks P, National Eating Disorder Research Consortium, Aouad P, et al. Screening, assessment and diagnosis in the eating disorders: findings from a rapid review. J Eat Disord. 2022;10:78. https:\/\/doi.org\/10.1186\/s40337-022-00597-8.","journal-title":"J Eat Disord"},{"issue":"3","key":"1248_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1176\/ajp.154.3.313","volume":"154","author":"PK Keel","year":"1997","unstructured":"Keel PK, Mitchell JE. Outcome in bulimia nervosa. Am J Psychiatry. 1997;154(3):313\u201321. https:\/\/doi.org\/10.1176\/ajp.154.3.313.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1248_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0272-7358(98)00014-2","volume":"18","author":"KM Pike","year":"1998","unstructured":"Pike KM. Long-term course of anorexia nervosa. Clin Psychol Rev. 1998;18(4):447\u201375. https:\/\/doi.org\/10.1016\/S0272-7358(98)00014-2.","journal-title":"Clin Psychol Rev"},{"key":"1248_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/10640260903585532","volume":"18","author":"D Linville","year":"2010","unstructured":"Linville D, Benton A, O\u2019Neil M, Sturm K. Medical providers\u2019 screening, training and intervention practices for eating disorders. Eat Disord. 2010;18:110\u201331. https:\/\/doi.org\/10.1080\/10640260903585532.","journal-title":"Eat Disord"},{"key":"1248_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40337-022-00543-8","volume":"10","author":"M Nicula","year":"2022","unstructured":"Nicula M, Pellegrini D, Grennan L, Bhatnagar N, McVey G, Couturier J. Help-seeking attitudes and behaviours among youth with eating disorders: a scoping review. J Eat Disord. 2022;10:21. https:\/\/doi.org\/10.1186\/s40337-022-00543-8.","journal-title":"J Eat Disord"},{"key":"1248_CR9","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.3390\/nu15173851","volume":"15","author":"O Horovitz","year":"2023","unstructured":"Horovitz O, Argyrides M. Orthorexia and orthorexia nervosa: a comprehensive examination of prevalence, risk factors, diagnosis, and treatment. Nutrients. 2023;15:3851. https:\/\/doi.org\/10.3390\/nu15173851.","journal-title":"Nutrients"},{"key":"1248_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40279-016-0564-3","volume":"47","author":"L Mitchell","year":"2017","unstructured":"Mitchell L, Murray SB, Cobley S, Hackett D, Gifford J, Capling L, et al. Muscle dysmorphia symptomatology and associated psychological features in bodybuilders and non-bodybuilder resistance trainers: a systematic review and meta-analysis. Sports Med. 2017;47:233\u201359. https:\/\/doi.org\/10.1007\/s40279-016-0564-3.","journal-title":"Sports Med"},{"issue":"5","key":"1248_CR11","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/ajcn\/nqy342","volume":"109","author":"M Galmiche","year":"2019","unstructured":"Galmiche M, D\u00e9chelotte P, Lambert G, Tavolacci MP. Prevalence of eating disorders over the 2000\u20132018 period: a systematic literature review. Am J Clin Nutr. 2019;109(5):1402\u201313. https:\/\/doi.org\/10.1093\/ajcn\/nqy342.","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"1248_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/YCO.0000000000000739","volume":"34","author":"AE Van Eeden","year":"2021","unstructured":"Van Eeden AE, Van Hoeken D, Hoek HW. Incidence, prevalence and mortality of anorexia nervosa and bulimia nervosa. Curr Opin Psychiatry. 2021;34(6):515\u201324. https:\/\/doi.org\/10.1097\/YCO.0000000000000739.","journal-title":"Curr Opin Psychiatry"},{"issue":"6","key":"1248_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/YCO.0000000000000750","volume":"34","author":"A Keski-Rahkonen","year":"2021","unstructured":"Keski-Rahkonen A. Epidemiology of binge eating disorder: prevalence, course, comorbidity, and risk factors. Curr Opin Psychiatry. 2021;34(6):525\u201331. https:\/\/doi.org\/10.1097\/YCO.0000000000000750.","journal-title":"Curr Opin Psychiatry"},{"key":"1248_CR14","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/archgenpsychiatry.2011.74","volume":"68","author":"J Arcelus","year":"2011","unstructured":"Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia nervosa and other eating disorders: a meta-analysis of 36 studies. Arch Gen Psychiatry. 2011;68:724. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.74.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"1248_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/eat.22501","volume":"49","author":"MM Fichter","year":"2016","unstructured":"Fichter MM, Quadflieg N. Mortality in eating disorders\u2014results of a large prospective clinical longitudinal study. Int J Eat Disord. 2016;49(4):391\u2013401. https:\/\/doi.org\/10.1002\/eat.22501.","journal-title":"Int J Eat Disord"},{"key":"1248_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/wps.20904","volume":"20","author":"N Auger","year":"2021","unstructured":"Auger N, Potter BJ, Ukah UV, Low N, Isra\u00ebl M, Steiger H, et al. Anorexia nervosa and the long-term risk of mortality in women. World Psychiatry. 2021;20:448\u20139. https:\/\/doi.org\/10.1002\/wps.20904.","journal-title":"World Psychiatry"},{"issue":"6","key":"1248_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/YCO.0000000000000641","volume":"33","author":"D Van Hoeken","year":"2020","unstructured":"Van Hoeken D, Hoek HW. Review of the burden of eating disorders: mortality, disability, costs, quality of life, and family burden. Curr Opin Psychiatry. 2020;33(6):521\u20137. https:\/\/doi.org\/10.1097\/YCO.0000000000000641.","journal-title":"Curr Opin Psychiatry"},{"key":"1248_CR18","unstructured":"Deloitte Access Economics. The social and economic cost of eating disorders in the United States of America: a report for the strategic training initiative for the prevention of eating disorders and the academy for eating disorders. 2020 [cited 2025 Jan 12]. https:\/\/www.hsph.harvard.edu\/striped\/report-economic-costs-of-eating-disorders\/. Accessed 12 Jan 2025."},{"key":"1248_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psychres.2014.05.002","volume":"219","author":"LA-D Winkler","year":"2014","unstructured":"Winkler LA-D, Christiansen E, Lichtenstein MB, Hansen NB, Bilenberg N, St\u00f8ving RK. Quality of life in eating disorders: a meta-analysis. Psychiatry Res. 2014;219:1\u20139. https:\/\/doi.org\/10.1016\/j.psychres.2014.05.002.","journal-title":"Psychiatry Res"},{"key":"1248_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222777","volume":"14","author":"XY Wu","year":"2019","unstructured":"Wu XY, Yin WQ, Sun HW, Yang SX, Li XY, Liu HQ. The association between disordered eating and health-related quality of life among children and adolescents: a systematic review of population-based studies. PLoS ONE. 2019;14:e0222777. https:\/\/doi.org\/10.1371\/journal.pone.0222777.","journal-title":"PLoS ONE"},{"key":"1248_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.psc.2019.01.009","volume":"42","author":"D Gibson","year":"2019","unstructured":"Gibson D, Workman C, Mehler PS. Medical complications of anorexia nervosa and bulimia nervosa. Psychiatr Clin North Am. 2019;42:263\u201374. https:\/\/doi.org\/10.1016\/j.psc.2019.01.009.","journal-title":"Psychiatr Clin North Am"},{"issue":"5","key":"1248_CR22","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/eat.23486","volume":"54","author":"J Streatfeild","year":"2021","unstructured":"Streatfeild J, Hickson J, Austin SB, Hutcheson R, Kandel JS, Lampert JG, et al. Social and economic cost of eating disorders in the United States: evidence to inform policy action. Int J Eat Disord. 2021;54(5):851\u201368. https:\/\/doi.org\/10.1002\/eat.23486.","journal-title":"Int J Eat Disord"},{"issue":"1","key":"1248_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024179","volume":"9","author":"P S\u00f6dersten","year":"2019","unstructured":"S\u00f6dersten P, Brodin U, Sj\u00f6berg J, Zandian M, Bergh C. Treatment outcomes for eating disorders in Sweden: data from the national quality registry. BMJ Open. 2019;9(1):e024179. https:\/\/doi.org\/10.1136\/bmjopen-2018-024179.","journal-title":"BMJ Open"},{"key":"1248_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4088\/JCP.15m10393","volume":"78","author":"KT Eddy","year":"2017","unstructured":"Eddy KT, Tabri N, Thomas JJ, Murray HB, Keshaviah A, Hastings E, et al. Recovery from anorexia nervosa and bulimia nervosa at 22-year follow-up. J Clin Psychiatry. 2017;78:184\u20139. https:\/\/doi.org\/10.4088\/JCP.15m10393.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1248_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/eat.20978","volume":"45","author":"S Wonderlich","year":"2012","unstructured":"Wonderlich S, Mitchell JE, Crosby RD, Myers TC, Kadlec K, LaHaise K, et al. Minimizing and treating chronicity in the eating disorders: a clinical overview. Int J Eat Disord. 2012;45(4):467\u201375. https:\/\/doi.org\/10.1002\/eat.20978.","journal-title":"Int J Eat Disord"},{"key":"1248_CR26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12888-014-0258-z","volume":"14","author":"S Schlegl","year":"2014","unstructured":"Schlegl S, Quadflieg N, L\u00f6we B, Cuntz U, Voderholzer U. Specialized inpatient treatment of adult anorexia nervosa: effectiveness and clinical significance of changes. BMC Psychiatry. 2014;14:258. https:\/\/doi.org\/10.1186\/s12888-014-0258-z.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"1248_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/eat.22838","volume":"51","author":"J Linardon","year":"2018","unstructured":"Linardon J, Wade TD. How many individuals achieve symptom abstinence following psychological treatments for bulimia nervosa? A meta-analytic review. Int J Eat Disord. 2018;51(4):287\u201394. https:\/\/doi.org\/10.1002\/eat.22838.","journal-title":"Int J Eat Disord"},{"issue":"8","key":"1248_CR28","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/eat.22897","volume":"51","author":"J Linardon","year":"2018","unstructured":"Linardon J. Rates of abstinence following psychological or behavioral treatments for binge-eating disorder: meta-analysis. Int J Eat Disord. 2018;51(8):785\u201397. https:\/\/doi.org\/10.1002\/eat.22897.","journal-title":"Int J Eat Disord"},{"key":"1248_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0132","author":"E Attia","year":"2025","unstructured":"Attia E, Walsh BT. Eating disorders: a review. JAMA. 2025. https:\/\/doi.org\/10.1001\/jama.2025.0132.","journal-title":"JAMA"},{"issue":"1","key":"1248_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/14740338.2018.1395854","volume":"17","author":"NT Bello","year":"2018","unstructured":"Bello NT, Yeomans BL. Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder. Expert Opin Drug Saf. 2018;17(1):17\u201323. https:\/\/doi.org\/10.1080\/14740338.2018.1395854.","journal-title":"Expert Opin Drug Saf"},{"key":"1248_CR31","unstructured":"Academy for Eating Disorders. A guide to selecting evidence-based psychological therapies for eating disorders. 2020 [cited 2025 Jan 21]. https:\/\/higherlogicdownload.s3.amazonaws.com\/AEDWEB\/27a3b69a-8aae-45b2-a04c-2a078d02145d\/UploadedImages\/Publications_Slider\/FINAL_AED_Psycholohgical_book.pdf. Accessed 21 Jan 2025."},{"issue":"2","key":"1248_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1176\/appi.ajp.23180001","volume":"180","author":"C Crone","year":"2023","unstructured":"Crone C, Fochtmann LJ, Attia E, Boland R, Escobar J, Fornari V, et al. The American Psychiatric Association Practice guideline for the treatment of patients with eating disorders. Am J Psychiatry. 2023;180(2):167\u201371. https:\/\/doi.org\/10.1176\/appi.ajp.23180001.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1248_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/15374416.2022.2109650","volume":"52","author":"N Datta","year":"2023","unstructured":"Datta N, Matheson BE, Citron K, Van Wye EM, Lock JD. Evidence based update on psychosocial treatments for eating disorders in children and adolescents. J Clin Child Adolesc Psychol. 2023;52(2):159\u201370. https:\/\/doi.org\/10.1080\/15374416.2022.2109650.","journal-title":"J Clin Child Adolesc Psychol"},{"issue":"4","key":"1248_CR34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/erv.2683","volume":"27","author":"E van den Berg","year":"2019","unstructured":"van den Berg E, Houtzager L, de Vos J, Daemen I, Katsaragaki G, Karyotaki E, et al. Meta-analysis on the efficacy of psychological treatments for anorexia nervosa. Eur Eat Disord Rev. 2019;27(4):331\u201351. https:\/\/doi.org\/10.1002\/erv.2683.","journal-title":"Eur Eat Disord Rev"},{"issue":"3","key":"1248_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S2215-0366(20)30566-6","volume":"8","author":"M Solmi","year":"2021","unstructured":"Solmi M, Wade TD, Byrne S, Del Giovane C, Fairburn CG, Ostinelli EG, et al. Comparative efficacy and acceptability of psychological interventions for the treatment of adult outpatients with anorexia nervosa: a systematic review and network meta-analysis. Lancet Psychiatry. 2021;8(3):215\u201324. https:\/\/doi.org\/10.1016\/S2215-0366(20)30566-6.","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"1248_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/YCO.0b013e328365a30e","volume":"26","author":"AE Kass","year":"2013","unstructured":"Kass AE, Kolko RP, Wilfley DE. Psychological treatments for eating disorders. Curr Opin Psychiatry. 2013;26(6):549\u201355. https:\/\/doi.org\/10.1097\/YCO.0b013e328365a30e.","journal-title":"Curr Opin Psychiatry"},{"key":"1248_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40337-023-00886-w","volume":"11","author":"H Russell","year":"2023","unstructured":"Russell H, Aouad P, Le A, Marks P, Maloney D, National Eating Disorder Research Consortium, et al. Psychotherapies for eating disorders: findings from a rapid review. J Eat Disord. 2023;11:175. https:\/\/doi.org\/10.1186\/s40337-023-00886-w.","journal-title":"J Eat Disord"},{"issue":"6","key":"1248_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1176\/appi.ajp.2018.18101125","volume":"176","author":"E Attia","year":"2019","unstructured":"Attia E, Steinglass JE, Walsh BT, Wang Y, Wu P, Schreyer C, et al. Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial. Am J Psychiatry. 2019;176(6):449\u201356. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18101125.","journal-title":"Am J Psychiatry"},{"key":"1248_CR39","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/s41591-023-02455-9","volume":"29","author":"SK Peck","year":"2023","unstructured":"Peck SK, Shao S, Gruen T, Yang K, Babakanian A, Trim J, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023;29:1947\u201353. https:\/\/doi.org\/10.1038\/s41591-023-02455-9.","journal-title":"Nat Med"},{"key":"1248_CR40","doi-asserted-by":"publisher","first-page":"e787","DOI":"10.4088\/JCP.14m09299","volume":"76","author":"CA Levinson","year":"2015","unstructured":"Levinson CA, Rodebaugh TL, Fewell L, Kass AE, Riley EN, Stark L, et al. D-cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial. J Clin Psychiatry. 2015;76:e787\u201393. https:\/\/doi.org\/10.4088\/JCP.14m09299.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"1248_CR41","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1007\/s40519-022-01455-x","volume":"27","author":"L Calabrese","year":"2022","unstructured":"Calabrese L, Scolnick B, Zupec-Kania B, Beckwith C, Costello K, Frank GKW. Ketogenic diet and ketamine infusion treatment to target chronic persistent eating disorder psychopathology in anorexia nervosa: a pilot study. Eat Weight Disord. 2022;27(8):3751\u20137. https:\/\/doi.org\/10.1007\/s40519-022-01455-x.","journal-title":"Eat Weight Disord"},{"key":"1248_CR42","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m11585","volume":"79","author":"PK Fazeli","year":"2018","unstructured":"Fazeli PK, Lawson EA, Faje AT, Eddy KT, Lee H, Fiedorek FT, et al. Treatment with a ghrelin agonist in outpatient women with anorexia nervosa: a randomized clinical trial. J Clin Psychiatry. 2018;79:17m11585. https:\/\/doi.org\/10.4088\/JCP.17m11585.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"1248_CR43","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1210\/jc.2019-00828","volume":"104","author":"A Kimball","year":"2019","unstructured":"Kimball A, Schorr M, Meenaghan E, Bachmann KN, Eddy KT, Misra M, et al. A randomized placebo-controlled trial of low-dose testosterone therapy in women with anorexia nervosa. J Clin Endocrinol Metab. 2019;104(10):4347\u201355. https:\/\/doi.org\/10.1210\/jc.2019-00828.","journal-title":"J Clin Endocrinol Metab"},{"key":"1248_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003495-200161010-00011","volume":"61","author":"N Bhana","year":"2001","unstructured":"Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61:111\u201361. https:\/\/doi.org\/10.2165\/00003495-200161010-00011.","journal-title":"Drugs"},{"issue":"1","key":"1248_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9740\/mhc.2025.02.001","volume":"15","author":"DL Stutzman","year":"2025","unstructured":"Stutzman DL. Use of atypical antipsychotics in individuals with anorexia nervosa. Ment Health Clin. 2025;15(1):1\u20138. https:\/\/doi.org\/10.9740\/mhc.2025.02.001.","journal-title":"Ment Health Clin"},{"key":"1248_CR46","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1186\/s12888-024-06215-y","volume":"24","author":"O Said","year":"2024","unstructured":"Said O, Stringer D, Sengun Filiz E, Mutwalli H, Bektas S, Akkese MN, et al. Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study. BMC Psychiatry. 2024;24:779. https:\/\/doi.org\/10.1186\/s12888-024-06215-y.","journal-title":"BMC Psychiatry"},{"key":"1248_CR47","doi-asserted-by":"publisher","first-page":"e757","DOI":"10.4088\/JCP.12r07691","volume":"73","author":"T Kishi","year":"2012","unstructured":"Kishi T, Kafantaris V, Sunday S, Sheridan EM, Correll CU. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry. 2012;73:e757-766. https:\/\/doi.org\/10.4088\/JCP.12r07691.","journal-title":"J Clin Psychiatry"},{"key":"1248_CR48","first-page":"26","volume":"61 Suppl 8","author":"RR Conley","year":"2000","unstructured":"Conley RR, Meltzer HY. Adverse events related to olanzapine. J Clin Psychiatry. 2000;61 Suppl 8:26\u20139 (discussion 30).","journal-title":"J Clin Psychiatry"},{"key":"1248_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/jox12010004","volume":"12","author":"M Coppola","year":"2022","unstructured":"Coppola M, Bevione F, Mondola R. Psilocybin for treating psychiatric disorders: a psychonaut legend or a promising therapeutic perspective? J Xenobiot. 2022;12:41\u201352. https:\/\/doi.org\/10.3390\/jox12010004.","journal-title":"J Xenobiot"},{"key":"1248_CR50","doi-asserted-by":"publisher","first-page":"8221","DOI":"10.1038\/s41467-023-44016-1","volume":"14","author":"J Wallach","year":"2023","unstructured":"Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, et al. Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential. Nat Commun. 2023;14:8221. https:\/\/doi.org\/10.1038\/s41467-023-44016-1.","journal-title":"Nat Commun"},{"key":"1248_CR51","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30214","author":"DB Goel","year":"2022","unstructured":"Goel DB, Zilate S. Potential therapeutic effects of psilocybin: a systematic review. Cureus. 2022. https:\/\/doi.org\/10.7759\/cureus.30214.","journal-title":"Cureus."},{"key":"1248_CR52","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41398-021-01706-y","volume":"11","author":"MK Doss","year":"2021","unstructured":"Doss MK, Pova\u017ean M, Rosenberg MD, Sepeda ND, Davis AK, Finan PH, et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. 2021;11:574. https:\/\/doi.org\/10.1038\/s41398-021-01706-y.","journal-title":"Transl Psychiatry"},{"key":"1248_CR53","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.yrtph.2011.01.006","volume":"59","author":"JV Amsterdam","year":"2011","unstructured":"Amsterdam JV, Opperhuizen A, Brink WVD. Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol. 2011;59:423\u20139. https:\/\/doi.org\/10.1016\/j.yrtph.2011.01.006.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"1248_CR54","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5960","volume":"7","author":"A Yerubandi","year":"2024","unstructured":"Yerubandi A, Thomas JE, Bhuiya NMMA, Harrington C, Villa Zapata L, Caballero J. Acute adverse effects of therapeutic doses of psilocybin: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(4):e245960. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.5960.","journal-title":"JAMA Netw Open"},{"key":"1248_CR55","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/jamapsychiatry.2016.3955","volume":"74","author":"D Mataix-Cols","year":"2017","unstructured":"Mataix-Cols D, de la Fern\u00e1ndez Cruz L, Monzani B, Rosenfield D, Andersson E, P\u00e9rez-Vigil A, et al. D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiat. 2017;74:501\u201310. https:\/\/doi.org\/10.1001\/jamapsychiatry.2016.3955.","journal-title":"JAMA Psychiat"},{"key":"1248_CR56","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41386-019-0552-z","volume":"45","author":"C Ebrahimi","year":"2020","unstructured":"Ebrahimi C, Gechter J, Lueken U, Schlagenhauf F, Wittchen H-U, Hamm AO, et al. Augmenting extinction learning with d-cycloserine reduces return of fear: a randomized, placebo-controlled fMRI study. Neuropsychopharmacology. 2020;45:499\u2013506. https:\/\/doi.org\/10.1038\/s41386-019-0552-z.","journal-title":"Neuropsychopharmacology"},{"key":"1248_CR57","unstructured":"Cycloserine. LiverTox Clin Res Inf Drug-Induc Liver Inj. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012 [cited 2025 Mar 3]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547876\/. Accessed 3 Mar 2025."},{"key":"1248_CR58","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.3390\/nu13114158","volume":"13","author":"JL Keeler","year":"2021","unstructured":"Keeler JL, Treasure J, Juruena MF, Kan C, Himmerich H. Ketamine as a treatment for anorexia nervosa: a narrative review. Nutrients. 2021;13:4158. https:\/\/doi.org\/10.3390\/nu13114158.","journal-title":"Nutrients"},{"key":"1248_CR59","volume-title":"Drug enforcement administration drug scheduling. StatPearls","author":"MJ Lopez","year":"2025","unstructured":"Lopez MJ, Preuss CV, Tadi P. Drug enforcement administration drug scheduling. StatPearls. Treasure Island: StatPearls Publishing; 2025."},{"key":"1248_CR60","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.4088\/JCP.17f11567","volume":"78","author":"C Andrade","year":"2017","unstructured":"Andrade C. Ketamine for depression, 1: clinical summary of issues related to efficacy, adverse effects, and mechanism of action: (clinical and practical psychopharmacolgy). J Clin Psychiatry. 2017;78:e415\u20139. https:\/\/doi.org\/10.4088\/JCP.17f11567.","journal-title":"J Clin Psychiatry"},{"key":"1248_CR61","volume-title":"Donepezil. StatPearls","author":"A Kumar","year":"2025","unstructured":"Kumar A, Gupta V, Sharma S. Donepezil. StatPearls. Treasure Island: StatPearls Publishing; 2025."},{"issue":"12","key":"1248_CR62","doi-asserted-by":"publisher","first-page":"6616","DOI":"10.1172\/JCI138532","volume":"130","author":"M Favier","year":"2020","unstructured":"Favier M, Janickova H, Justo D, Kljakic O, Runtz L, Natsheh JY, et al. Cholinergic dysfunction in the dorsal striatum promotes habit formation and maladaptive eating. J Clin Investig. 2020;130(12):6616\u201330. https:\/\/doi.org\/10.1172\/JCI138532.","journal-title":"J Clin Investig"},{"issue":"5","key":"1248_CR63","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1517\/13543780902810360","volume":"18","author":"AH Bucay","year":"2009","unstructured":"Bucay AH. Donepezil (aricept) as a treatment for anorexia nervosa: a very feasible therapeutic possibility. Expert Opin Investig Drugs. 2009;18(5):569\u201371. https:\/\/doi.org\/10.1517\/13543780902810360.","journal-title":"Expert Opin Investig Drugs"},{"key":"1248_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.749050","volume":"12","author":"K Mendoza-Herrera","year":"2021","unstructured":"Mendoza-Herrera K, Florio AA, Moore M, Marrero A, Tamez M, Bhupathiraju SN, et al. The leptin system and diet: a mini review of the current evidence. Front Endocrinol. 2021;12:749050. https:\/\/doi.org\/10.3389\/fendo.2021.749050.","journal-title":"Front Endocrinol"},{"issue":"6","key":"1248_CR65","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/andr.12774","volume":"8","author":"A Barbonetti","year":"2020","unstructured":"Barbonetti A, D\u2019Andrea S, Francavilla S. Testosterone replacement therapy. Andrology. 2020;8(6):1551\u201366. https:\/\/doi.org\/10.1111\/andr.12774.","journal-title":"Andrology"},{"key":"1248_CR66","volume-title":"Lipodystrophies. StatPearls","author":"K Quinn","year":"2025","unstructured":"Quinn K, Chauhan S, Purcell SM. Lipodystrophies. StatPearls. Treasure Island: StatPearls Publishing; 2025."},{"key":"1248_CR67","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41398-020-00977-1","volume":"10","author":"G Milos","year":"2020","unstructured":"Milos G, Antel J, Kaufmann L-K, Barth N, Koller A, Tan S, et al. Short-term metreleptin treatment of patients with anorexia nervosa: rapid on-set of beneficial cognitive, emotional, and behavioral effects. Transl Psychiatry. 2020;10:303. https:\/\/doi.org\/10.1038\/s41398-020-00977-1.","journal-title":"Transl Psychiatry"},{"key":"1248_CR68","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s00787-021-01778-7","volume":"31","author":"J Antel","year":"2022","unstructured":"Antel J, Tan S, Grabler M, Ludwig C, Lohkemper D, Brandenburg T, et al. Rapid amelioration of anorexia nervosa in a male adolescent during metreleptin treatment including recovery from hypogonadotropic hypogonadism. Eur Child Adolesc Psychiatry. 2022;31:1573\u20139. https:\/\/doi.org\/10.1007\/s00787-021-01778-7.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1248_CR69","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4137\/CCRep.S40196","volume":"9","author":"C Musso","year":"2016","unstructured":"Musso C, Major ML, Andres E, Simha V. Metreleptin treatment in three patients with generalized lipodystrophy. Clin Med Insights Case Rep. 2016;9:123\u20137. https:\/\/doi.org\/10.4137\/CCRep.S40196.","journal-title":"Clin Med Insights Case Rep"},{"key":"1248_CR70","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48303","author":"A Patel","year":"2023","unstructured":"Patel A, Arora GS, Roknsharifi M, Javed H, Kaur P. Relamorelin in gastroparesis and diabetic gastroparesis: a meta-analysis on its efficacy and safety. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.48303.","journal-title":"Cureus."},{"key":"1248_CR71","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1001\/jama.2024.20035","volume":"332","author":"K McCreedy","year":"2024","unstructured":"McCreedy K, von der Heydt J, Chauhan A, Shah R, Kang S, Platt E, et al. State policies regulating law enforcement access to prescription drug monitoring program testosterone prescription data. JAMA. 2024;332:1754\u20137. https:\/\/doi.org\/10.1001\/jama.2024.20035.","journal-title":"JAMA"},{"key":"1248_CR72","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.maturitas.2009.01.012","volume":"63","author":"CL Shufelt","year":"2009","unstructured":"Shufelt CL, Braunstein GD. Safety of testosterone use in women. Maturitas. 2009;63:63\u20136. https:\/\/doi.org\/10.1016\/j.maturitas.2009.01.012.","journal-title":"Maturitas"},{"key":"1248_CR73","first-page":"27","volume":"21","author":"WW IsHak","year":"2024","unstructured":"IsHak WW, Meyer A, Freire L. Overview of psychiatric medications in the pipeline in phase III trials as of June 1, 2024: a systematic review. Innov Clin Neurosci. 2024;21:27\u201347.","journal-title":"Innov Clin Neurosci"},{"key":"1248_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119778","author":"S Ramadan","year":"2025","unstructured":"Ramadan S, Tay L, Kaur H, Parrish T, Abdelmoteleb S, Totlani J, et al. Bipolar disorder: systematic review of approved psychiatric medications (2008-2024) and pipeline phase-3 medications. J Affect Disord. 2025. https:\/\/doi.org\/10.1016\/j.jad.2025.119778.","journal-title":"J Affect Disord"},{"key":"1248_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2024-11-2","volume":"14","author":"E Tadros","year":"2025","unstructured":"Tadros E, Keerthana S, Padder S, Totlani J, Hirsch D, Kaidbay DN, et al. Anxiety disorders, PTSD and OCD: systematic review of approved psychiatric medications (2008\u20132024) and pipeline phase III medications. Drugs Context. 2025;14:1\u201324. https:\/\/doi.org\/10.7573\/dic.2024-11-2.","journal-title":"Drugs Context"},{"key":"1248_CR76","doi-asserted-by":"publisher","first-page":"885","DOI":"10.30574\/wjarr.2024.21.3.0705","volume":"21","author":"WW IsHak","year":"2024","unstructured":"IsHak WW, Totlani J, Murphy N, Renteria S, Chang T, Abdelsalam R, et al. Overview of approved psychiatric medications 2008\u20132023: a systematic review. World J Adv Res Rev. 2024;21:885\u2013915. https:\/\/doi.org\/10.30574\/wjarr.2024.21.3.0705.","journal-title":"World J Adv Res Rev."},{"key":"1248_CR77","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1186\/s12888-025-07141-3","volume":"25","author":"WW IsHak","year":"2025","unstructured":"IsHak WW, Hirsch D, Renteria S, Totlani J, Murphy N, Chang T, et al. Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications. BMC Psychiatry. 2025;25:939. https:\/\/doi.org\/10.1186\/s12888-025-07141-3.","journal-title":"BMC Psychiatry"},{"issue":"6","key":"1248_CR78","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/YCO.0000000000000360","volume":"30","author":"A Hilbert","year":"2017","unstructured":"Hilbert A, Hoek HW, Schmidt R. Evidence-based clinical guidelines for eating disorders: international comparison. Curr Opin Psychiatry. 2017;30(6):423\u201337. https:\/\/doi.org\/10.1097\/YCO.0000000000000360.","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"1248_CR79","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.molmed.2024.02.009","volume":"30","author":"C Bryson","year":"2024","unstructured":"Bryson C, Douglas D, Schmidt U. Established and emerging treatments for eating disorders. Trends Mol Med. 2024;30(4):392\u2013402. https:\/\/doi.org\/10.1016\/j.molmed.2024.02.009.","journal-title":"Trends Mol Med"},{"issue":"1","key":"1248_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167606","volume":"12","author":"M Kekic","year":"2017","unstructured":"Kekic M, McClelland J, Bartholdy S, Boysen E, Musiat P, Dalton B, et al. Single-session transcranial direct current stimulation temporarily improves symptoms, mood, and self-regulatory control in bulimia nervosa: a randomised controlled trial. PLoS ONE. 2017;12(1):e0167606. https:\/\/doi.org\/10.1371\/journal.pone.0167606.","journal-title":"PLoS ONE"},{"key":"1248_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/nu10111806","volume":"10","author":"C Imperatori","year":"2018","unstructured":"Imperatori C, Mancini M, Della Marca G, Valenti EM, Farina B. Feedback-based treatments for eating disorders and related symptoms: a systematic review of the literature. Nutrients. 2018;10:1806. https:\/\/doi.org\/10.3390\/nu10111806.","journal-title":"Nutrients"},{"issue":"3","key":"1248_CR82","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/cpp.2622","volume":"28","author":"G Riva","year":"2021","unstructured":"Riva G, Malighetti C, Serino S. Virtual reality in the treatment of eating disorders. Clin Psychol Psychother. 2021;28(3):477\u201388. https:\/\/doi.org\/10.1002\/cpp.2622.","journal-title":"Clin Psychol Psychother"},{"key":"1248_CR83","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11920-022-01321-8","volume":"24","author":"L Gallop","year":"2022","unstructured":"Gallop L, Flynn M, Campbell IC, Schmidt U. Neuromodulation and eating disorders. Curr Psychiatry Rep. 2022;24:61\u20139. https:\/\/doi.org\/10.1007\/s11920-022-01321-8.","journal-title":"Curr Psychiatry Rep"},{"issue":"12","key":"1248_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S003329172400148X","volume":"54","author":"CM Grilo","year":"2024","unstructured":"Grilo CM, Ivezaj V, Yurkow S, Tek C, Wiedemann AA, Gueorguieva R. Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial. Psychol Med. 2024;54(12):1\u201311. https:\/\/doi.org\/10.1017\/S003329172400148X.","journal-title":"Psychol Med"},{"issue":"5","key":"1248_CR85","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/npp.2015.275","volume":"41","author":"SL McElroy","year":"2016","unstructured":"McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016;41(5):1251\u201360. https:\/\/doi.org\/10.1038\/npp.2015.275.","journal-title":"Neuropsychopharmacology"},{"key":"1248_CR86","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/jamapsychiatry.2017.1889","volume":"74","author":"JI Hudson","year":"2017","unstructured":"Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiat. 2017;74:903\u201310. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1889.","journal-title":"JAMA Psychiat"},{"key":"1248_CR87","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jamapsychiatry.2014.2162","volume":"72","author":"SL McElroy","year":"2015","unstructured":"McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiat. 2015;72:235. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.2162.","journal-title":"JAMA Psychiat"},{"key":"1248_CR88","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.psychres.2019.01.066","volume":"273","author":"LC Quilty","year":"2019","unstructured":"Quilty LC, Allen TA, Davis C, Knyahnytska Y, Kaplan AS. A randomized comparison of long acting methylphenidate and cognitive behavioral therapy in the treatment of binge eating disorder. Psychiatry Res. 2019;273:467\u201374. https:\/\/doi.org\/10.1016\/j.psychres.2019.01.066.","journal-title":"Psychiatry Res"},{"key":"1248_CR89","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m13068","author":"SL McElroy","year":"2020","unstructured":"McElroy SL, Hudson JI, Grilo CM, Guerdjikova AI, Deng L, Koblan KS, et al. Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, flexible-dose clinical trial. J Clin Psychiatry. 2020. https:\/\/doi.org\/10.4088\/JCP.19m13068.","journal-title":"J Clin Psychiatry"},{"key":"1248_CR90","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1017\/S1092852920000863","volume":"25","author":"J Tsai","year":"2020","unstructured":"Tsai J, Navia B, McElroy SL, Hudson JI, Grilo CM, Goldman R, et al. 170 efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, double-blind, fixed-dose trial. CNS Spectr. 2020;25:308\u20139. https:\/\/doi.org\/10.1017\/S1092852920000863.","journal-title":"CNS Spectr"},{"issue":"12","key":"1248_CR91","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.20220267","volume":"179","author":"CM Grilo","year":"2022","unstructured":"Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. Naltrexone-bupropion and behavior therapy, alone and combined, for binge-eating disorder: randomized double-blind placebo-controlled trial. Am J Psychiatry. 2022;179(12):927\u201337. https:\/\/doi.org\/10.1176\/appi.ajp.20220267.","journal-title":"Am J Psychiatry"},{"issue":"16","key":"1248_CR92","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.1017\/S0033291723001800","volume":"53","author":"CM Grilo","year":"2023","unstructured":"Grilo CM, Lydecker JA, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychol Med. 2023;53(16):7775\u201384. https:\/\/doi.org\/10.1017\/S0033291723001800.","journal-title":"Psychol Med"},{"key":"1248_CR93","first-page":"17","volume":"15","author":"AI Guerdjikova","year":"2018","unstructured":"Guerdjikova AI, Williams S, Blom TJ, Mori N, McElroy SL. Combination phentermine-topiramate extended release for the treatment of binge eating disorder: an open-label, prospective study. Innov Clin Neurosci. 2018;15:17\u201321.","journal-title":"Innov Clin Neurosci"},{"issue":"2","key":"1248_CR94","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/eat.23192","volume":"53","author":"DL Safer","year":"2020","unstructured":"Safer DL, Adler S, Sethi S, Bentley JP, Toyama H, Pajarito S, et al. A randomized, placebo\u2010controlled crossover trial of phentermine\u2010topiramate ER in patients with binge\u2010eating disorder and bulimia nervosa. Int J Eat Disord. 2020;53(2):266\u201377. https:\/\/doi.org\/10.1002\/eat.23192.","journal-title":"Int J Eat Disord"},{"issue":"7","key":"1248_CR95","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/eat.23078","volume":"52","author":"JE Grant","year":"2019","unstructured":"Grant JE, Valle S, Cavic E, Redden SA, Chamberlain SR. A double\u2010blind, placebo\u2010controlled study of vortioxetine in the treatment of binge\u2010eating disorder. Int J Eat Disord. 2019;52(7):786\u201394. https:\/\/doi.org\/10.1002\/eat.23078.","journal-title":"Int J Eat Disord"},{"issue":"3","key":"1248_CR96","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/eat.22114","volume":"46","author":"SL McElroy","year":"2013","unstructured":"McElroy SL, Guerdjikova AI, Blom TJ, Crow SJ, Memisoglu A, Silverman BL, et al. A placebo\u2010controlled pilot study of the novel opioid receptor antagonist ALKS\u201033 in binge eating disorder. Int J Eat Disord. 2013;46(3):239\u201345. https:\/\/doi.org\/10.1002\/eat.22114.","journal-title":"Int J Eat Disord"},{"issue":"11","key":"1248_CR97","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/eat.24039","volume":"56","author":"SL McElroy","year":"2023","unstructured":"McElroy SL, Coloma PM, Berger B, Guerdjikova AI, Joyce JM, Liebowitz MR, et al. Efficacy, safety, and tolerability of nivasorexant in adults with binge\u2010eating disorder: a randomized, phase II proof of concept trial. Int J Eat Disord. 2023;56(11):2120\u201330. https:\/\/doi.org\/10.1002\/eat.24039.","journal-title":"Int J Eat Disord"},{"key":"1248_CR98","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.euroneuro.2021.08.001","volume":"53","author":"E Schneider","year":"2021","unstructured":"Schneider E, Higgs S, Dourish CT. Lisdexamfetamine and binge-eating disorder: a systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder. Eur Neuropsychopharmacol. 2021;53:49\u201378. https:\/\/doi.org\/10.1016\/j.euroneuro.2021.08.001.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1248_CR99","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40261-015-0354-y","volume":"36","author":"JC Ermer","year":"2016","unstructured":"Ermer JC, Pennick M, Frick G. Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy. Clin Drug Investig. 2016;36:341\u201356. https:\/\/doi.org\/10.1007\/s40261-015-0354-y.","journal-title":"Clin Drug Investig"},{"key":"1248_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsgos.2023.08.016","author":"KR Griffiths","year":"2023","unstructured":"Griffiths KR, Breukelaar IA, Harvie G, Yang J, Foster SL, Harris AW, et al. Functional connectivity mechanisms underlying symptom reduction following lisdexamfetamine treatment in binge-eating disorder: a clinical trial. Biol Psychiatry Glob Open Sci. 2023. https:\/\/doi.org\/10.1016\/j.bpsgos.2023.08.016.","journal-title":"Biol Psychiatry Glob Open Sci."},{"key":"1248_CR101","first-page":"24532","volume":"72","author":"Drug Enforcement Administration, Department of Justice","year":"2007","unstructured":"Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of lisdexamfetamine into schedule II. Final rule. Fed Regist. 2007;72:24532\u20134.","journal-title":"Fed Regist"},{"issue":"2","key":"1248_CR102","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/17425255.2018.1420163","volume":"14","author":"K Ward","year":"2018","unstructured":"Ward K, Citrome L. Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder. Expert Opin Drug Metab Toxicol. 2018;14(2):229\u201338. https:\/\/doi.org\/10.1080\/17425255.2018.1420163.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1248_CR103","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1060028013510699","volume":"48","author":"A Sharma","year":"2014","unstructured":"Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48:209\u201325. https:\/\/doi.org\/10.1177\/1060028013510699.","journal-title":"Ann Pharmacother"},{"key":"1248_CR104","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jad.2021.05.119","volume":"292","author":"A Bahji","year":"2021","unstructured":"Bahji A, Mesbah-Oskui L. Comparative efficacy and safety of stimulant-type medications for depression: a systematic review and network meta-analysis. J Affect Disord. 2021;292:416\u201323. https:\/\/doi.org\/10.1016\/j.jad.2021.05.119.","journal-title":"J Affect Disord"},{"key":"1248_CR105","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4088\/pcc.v02n0502","volume":"2","author":"WA Morton","year":"2000","unstructured":"Morton WA, Stockton GG. Methylphenidate abuse and psychiatric side effects. Prim Care Companion CNS Disord. 2000;2:159\u201364. https:\/\/doi.org\/10.4088\/pcc.v02n0502.","journal-title":"Prim Care Companion CNS Disord"},{"key":"1248_CR106","volume-title":"Methylphenidate. StatPearls","author":"C Verghese","year":"2025","unstructured":"Verghese C, Patel P, Abdijadid S. Methylphenidate. StatPearls. Treasure Island: StatPearls Publishing; 2025."},{"key":"1248_CR107","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41386-018-0285-4","volume":"44","author":"P Di Ciano","year":"2019","unstructured":"Di Ciano P, Mansouri E, Tong J, Wilson AA, Houle S, Boileau I, et al. Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans. Neuropsychopharmacology. 2019;44:1284\u201390. https:\/\/doi.org\/10.1038\/s41386-018-0285-4.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"1248_CR108","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/JCP.0000000000001575","volume":"42","author":"LA Adler","year":"2022","unstructured":"Adler LA, Adams J, Madera-McDonough J, Kohegyi E, Hobart M, Chang D, et al. Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit\/hyperactivity disorder: results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials. J Clin Psychopharmacol. 2022;42(5):429\u201339. https:\/\/doi.org\/10.1097\/JCP.0000000000001575.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1248_CR109","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1017\/S1092852920001406","volume":"26","author":"CM Grilo","year":"2021","unstructured":"Grilo CM, McElroy SL, Hudson JI, Tsai J, Navia B, Goldman R, et al. Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial. CNS Spectr. 2021;26(5):481\u201390. https:\/\/doi.org\/10.1017\/S1092852920001406.","journal-title":"CNS Spectr"},{"issue":"12","key":"1248_CR110","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1038\/npp.2015.124","volume":"40","author":"KS Koblan","year":"2015","unstructured":"Koblan KS, Hopkins SC, Sarma K, Jin F, Goldman R, Kollins SH, et al. Dasotraline for the treatment of attention-deficit\/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology. 2015;40(12):2745\u201352. https:\/\/doi.org\/10.1038\/npp.2015.124.","journal-title":"Neuropsychopharmacology"},{"key":"1248_CR111","unstructured":"Sunovion Discontinues Dasotraline Program. 2020 [cited 2025 Mar 3]. https:\/\/www.businesswire.com\/news\/home\/20200513005363\/en\/Sunovion-Discontinues-Dasotraline-Program. Accessed 3 Mar 2025."},{"issue":"3","key":"1248_CR112","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ana.25423","volume":"85","author":"MJ Thorpy","year":"2019","unstructured":"Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359\u201370. https:\/\/doi.org\/10.1002\/ana.25423.","journal-title":"Ann Neurol"},{"key":"1248_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106587","volume":"110","author":"AI Guerdjikova","year":"2021","unstructured":"Guerdjikova AI, Romo-Nava F, Blom TJ, Mori N, McElroy SL. Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder. Contemp Clin Trials. 2021;110:106587. https:\/\/doi.org\/10.1016\/j.cct.2021.106587.","journal-title":"Contemp Clin Trials"},{"issue":"12","key":"1248_CR114","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1177\/0269881118796814","volume":"32","author":"LP Carter","year":"2018","unstructured":"Carter LP, Henningfield JE, Wang YG, Lu Y, Kelsh D, Vince B, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. J Psychopharmacol. 2018;32(12):1351\u201361. https:\/\/doi.org\/10.1177\/0269881118796814.","journal-title":"J Psychopharmacol"},{"key":"1248_CR115","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.sleep.2022.08.005","volume":"100","author":"A Malhotra","year":"2022","unstructured":"Malhotra A, Strollo PJ, Pepin J-L, Schweitzer P, Lammers GJ, Hedner J, et al. Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy. Sleep Med. 2022;100:165\u201373. https:\/\/doi.org\/10.1016\/j.sleep.2022.08.005.","journal-title":"Sleep Med"},{"issue":"3","key":"1248_CR116","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/sleep\/31.3.335","volume":"31","author":"HAD Fortuyn","year":"2008","unstructured":"Fortuyn HAD, Swinkels S, Buitelaar J, Renier WO, Furer JW, Rijnders CA, et al. High prevalence of eating disorders in narcolepsy with cataplexy: a case-control study. Sleep. 2008;31(3):335\u201341. https:\/\/doi.org\/10.1093\/sleep\/31.3.335.","journal-title":"Sleep"},{"key":"1248_CR117","doi-asserted-by":"publisher","first-page":"370","DOI":"10.14310\/horm.2002.1600","volume":"14","author":"GA Christou","year":"2015","unstructured":"Christou GA, Kiortsis DN. The efficacy and safety of the naltrexone\/bupropion combination for the treatment of obesity: an update. Hormones (Athens). 2015;14:370\u20135. https:\/\/doi.org\/10.14310\/horm.2002.1600.","journal-title":"Hormones (Athens)"},{"issue":"1","key":"1248_CR118","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clinthera.2020.10.010","volume":"43","author":"CM Grilo","year":"2021","unstructured":"Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R. Naltrexone + bupropion combination for the treatment of binge-eating disorder with obesity: a randomized, controlled pilot study. Clin Ther. 2021;43(1):112-122.e1. https:\/\/doi.org\/10.1016\/j.clinthera.2020.10.010.","journal-title":"Clin Ther"},{"issue":"5","key":"1248_CR119","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/ijo.2013.145","volume":"38","author":"G-J Wang","year":"2014","unstructured":"Wang G-J, Tomasi D, Volkow ND, Wang R, Telang F, Caparelli EC, et al. Effect of combined naltrexone and bupropion therapy on the brain\u2019s reactivity to food cues. Int J Obes. 2014;38(5):682\u20138. https:\/\/doi.org\/10.1038\/ijo.2013.145.","journal-title":"Int J Obes"},{"issue":"5","key":"1248_CR120","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"CM Apovian","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity\u2010related risk factors (COR\u2010II). Obesity. 2013;21(5):935\u201343. https:\/\/doi.org\/10.1002\/oby.20309.","journal-title":"Obesity"},{"issue":"3","key":"1248_CR121","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1345\/aph.1R501","volume":"47","author":"SM Smith","year":"2013","unstructured":"Smith SM, Meyer M, Trinkley KE. Phentermine\/topiramate for the treatment of obesity. Ann Pharmacother. 2013;47(3):340\u20139. https:\/\/doi.org\/10.1345\/aph.1R501.","journal-title":"Ann Pharmacother"},{"key":"1248_CR122","first-page":"446","volume":"38","author":"DJ Lonneman","year":"2013","unstructured":"Lonneman DJ, Rey JA, McKee BD. Phentermine\/topiramate extended-release capsules (Qsymia) for weight loss. Pharm Ther. 2013;38:446\u201352.","journal-title":"Pharm Ther"},{"issue":"6","key":"1248_CR123","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/head.12826","volume":"56","author":"SD Spritzer","year":"2016","unstructured":"Spritzer SD, Bravo TP, Drazkowski JF. Topiramate for treatment in patients with migraine and epilepsy. Headache. 2016;56(6):1081\u20135. https:\/\/doi.org\/10.1111\/head.12826.","journal-title":"Headache"},{"issue":"6","key":"1248_CR124","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/oby.23152","volume":"29","author":"X Lei","year":"2021","unstructured":"Lei X, Ruan J, Lai C, Sun Z, Yang X. Efficacy and safety of phentermine\/topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity. 2021;29(6):985\u201394. https:\/\/doi.org\/10.1002\/oby.23152.","journal-title":"Obesity"},{"key":"1248_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1134454","volume":"14","author":"PB Van Der Meer","year":"2023","unstructured":"Van Der Meer PB, Fuentes JJ, Kaptein AA, Schoones JW, De Waal MM, Goudriaan AE, et al. Therapeutic effect of psilocybin in addiction: a systematic review. Front Psychiatry. 2023;14:1134454. https:\/\/doi.org\/10.3389\/fpsyt.2023.1134454.","journal-title":"Front Psychiatry"},{"key":"1248_CR126","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3389\/fpsyt.2019.00771","volume":"10","author":"D Bennabi","year":"2019","unstructured":"Bennabi D, Haffen E, Van Waes V. Vortioxetine for cognitive enhancement in major depression: from animal models to clinical research. Front Psychiatry. 2019;10:771. https:\/\/doi.org\/10.3389\/fpsyt.2019.00771.","journal-title":"Front Psychiatry"},{"key":"1248_CR127","first-page":"36","volume":"40","author":"A D\u2019Agostino","year":"2015","unstructured":"D\u2019Agostino A, English CD, Rey JA. Vortioxetine (brintellix): a new serotonergic antidepressant. P T Peer Rev J Formul Manag. 2015;40:36\u201340.","journal-title":"P T Peer Rev J Formul Manag"},{"issue":"9","key":"1248_CR128","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1080\/17512433.2022.2118111","volume":"15","author":"J Gao","year":"2022","unstructured":"Gao J, Li J, Lu X, Yang J. Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder. Expert Rev Clin Pharmacol. 2022;15(9):1011\u20136. https:\/\/doi.org\/10.1080\/17512433.2022.2118111.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"1248_CR129","doi-asserted-by":"publisher","first-page":"128","DOI":"10.5114\/ppn.2023.132493","volume":"32","author":"WB Grywi\u0144ska","year":"2023","unstructured":"Grywi\u0144ska WB, G\u0142owacka A. Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment. Postepy Psychiatr Neurol. 2023;32(3):128\u201337. https:\/\/doi.org\/10.5114\/ppn.2023.132493.","journal-title":"Postepy Psychiatr Neurol"},{"key":"1248_CR130","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5139","author":"AMD Chaudhary","year":"2019","unstructured":"Chaudhary AMD, Khan MF, Dhillon SS, Naveed S. A review of samidorphan: a novel opioid antagonist. Cureus. 2019. https:\/\/doi.org\/10.7759\/cureus.5139.","journal-title":"Cureus."},{"key":"1248_CR131","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1021\/acs.jmedchem.3c01894","volume":"67","author":"JT Williams","year":"2024","unstructured":"Williams JT, Bolli MH, Brotschi C, Sifferlen T, Steiner MA, Treiber A, et al. Discovery of nivasorexant (ACT-539313): the first selective orexin-1 receptor antagonist (SO1RA) investigated in clinical trials. J Med Chem. 2024;67:2337\u201348. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01894.","journal-title":"J Med Chem"},{"issue":"5","key":"1248_CR132","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1143","volume":"11","author":"B Berger","year":"2023","unstructured":"Berger B, Kaufmann P, Berse M, Treiber A, Grignaschi N, Dingemanse J. Effect of nivasorexant (ACT \u2010539313), a selective orexin\u20101\u2010receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects. Pharmacol Res Perspect. 2023;11(5):e01143. https:\/\/doi.org\/10.1002\/prp2.1143.","journal-title":"Pharmacol Res Perspect"},{"key":"1248_CR133","doi-asserted-by":"publisher","first-page":"S729","DOI":"10.1016\/j.ajog.2023.06.041","volume":"230","author":"AC Hermesch","year":"2024","unstructured":"Hermesch AC, Kernberg AS, Layoun VR, Caughey AB. Oxytocin: physiology, pharmacology, and clinical application for labor management. Am J Obstet Gynecol. 2024;230:S729\u201339. https:\/\/doi.org\/10.1016\/j.ajog.2023.06.041.","journal-title":"Am J Obstet Gynecol"},{"key":"1248_CR134","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nature03701","volume":"435","author":"M Kosfeld","year":"2005","unstructured":"Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005;435:673\u20136. https:\/\/doi.org\/10.1038\/nature03701.","journal-title":"Nature"},{"issue":"10","key":"1248_CR135","doi-asserted-by":"publisher","first-page":"5407","DOI":"10.1016\/j.clnu.2021.08.011","volume":"40","author":"C-Y Chen","year":"2021","unstructured":"Chen C-Y, Chiang Y-C, Kuo T-C, Tam K-W, Loh E-W. Effects of intranasal oxytocin in food intake and craving: a meta-analysis of clinical trials. Clin Nutr. 2021;40(10):5407\u201316. https:\/\/doi.org\/10.1016\/j.clnu.2021.08.011.","journal-title":"Clin Nutr"},{"key":"1248_CR136","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.psyneuen.2011.02.015","volume":"36","author":"E MacDonald","year":"2011","unstructured":"MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011;36:1114\u201326. https:\/\/doi.org\/10.1016\/j.psyneuen.2011.02.015.","journal-title":"Psychoneuroendocrinology"},{"key":"1248_CR137","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jad.2023.06.068","volume":"338","author":"M Fornaro","year":"2023","unstructured":"Fornaro M, Mondin AM, Billeci M, Fusco A, De Prisco M, Caiazza C, et al. Psychopharmacology of eating disorders: systematic review and meta-analysis of randomized controlled trials. J Affect Disord. 2023;338:526\u201345. https:\/\/doi.org\/10.1016\/j.jad.2023.06.068.","journal-title":"J Affect Disord"},{"key":"1248_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115357","volume":"327","author":"A Argyrou","year":"2023","unstructured":"Argyrou A, Lappas AS, Bakaloudi DR, Tsekitsidi E, Mathioudaki E, Michou N, et al. Pharmacotherapy compared to placebo for people with bulimia nervosa: a systematic review and meta-analysis. Psychiatry Res. 2023;327:115357. https:\/\/doi.org\/10.1016\/j.psychres.2023.115357.","journal-title":"Psychiatry Res"},{"issue":"2","key":"1248_CR139","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","volume":"160","author":"SL McElroy","year":"2003","unstructured":"McElroy SL, Arnold LM, Shapira NA, Keck PE, Rosenthal NR, Karim MR, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(2):255\u201361. https:\/\/doi.org\/10.1176\/appi.ajp.160.2.255.","journal-title":"Am J Psychiatry"},{"key":"1248_CR140","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1017\/S1092852920001613","volume":"26","author":"M Nourredine","year":"2021","unstructured":"Nourredine M, Jurek L, Auffret M, Iceta S, Grenet G, Kassai B, et al. Efficacy and safety of topiramate in binge eating disorder: a systematic review and meta-analysis. CNS Spectr. 2021;26:459\u201367. https:\/\/doi.org\/10.1017\/S1092852920001613.","journal-title":"CNS Spectr"},{"issue":"3","key":"1248_CR141","doi-asserted-by":"publisher","first-page":"493","DOI":"10.9758\/cpn.23.1151","volume":"22","author":"F Mokhtari","year":"2024","unstructured":"Mokhtari F, Taghavi M, Mashayekh M. An efficient combination therapy with lisdexamfetamine dimesylate and topiramate in improving binge eating scale & metabolic profile in binge eating disorder: a randomized control trial. Clin Psychopharmacol Neurosci. 2024;22(3):493\u2013501. https:\/\/doi.org\/10.9758\/cpn.23.1151.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"1","key":"1248_CR142","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-23-0405","volume":"262","author":"KN Balantekin","year":"2024","unstructured":"Balantekin KN, Kretz MJ, Mietlicki-Baase EG. The emerging role of glucagon-like peptide 1 in binge eating. J Endocrinol. 2024;262(1):e230405. https:\/\/doi.org\/10.1530\/JOE-23-0405.","journal-title":"J Endocrinol"},{"key":"1248_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100080","volume":"7","author":"J Richards","year":"2023","unstructured":"Richards J, Bang N, Ratliff EL, Paszkowiak MA, Khorgami Z, Khalsa SS, et al. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study. Obes Pillars. 2023;7:100080. https:\/\/doi.org\/10.1016\/j.obpill.2023.100080.","journal-title":"Obes Pillars"},{"key":"1248_CR144","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/osp4.619","volume":"9","author":"KC Allison","year":"2023","unstructured":"Allison KC, Chao AM, Bruzas MB, McCuen-Wurst C, Jones E, McAllister C, et al. A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder. Obes Sci Pract. 2023;9:127\u201336. https:\/\/doi.org\/10.1002\/osp4.619.","journal-title":"Obes Sci Pract"},{"issue":"8","key":"1248_CR145","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.2174\/1570159X16666180108111532","volume":"16","author":"B Dalton","year":"2018","unstructured":"Dalton B, Bartholdy S, Campbell IC, Schmidt U. Neurostimulation in clinical and sub-clinical eating disorders: a systematic update of the literature. Curr Neuropharmacol. 2018;16(8):1174\u201392. https:\/\/doi.org\/10.2174\/1570159X16666180108111532.","journal-title":"Curr Neuropharmacol"},{"key":"1248_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.951186","volume":"13","author":"P Vigil","year":"2022","unstructured":"Vigil P, Mel\u00e9ndez J, Petkovic G, Del R\u00edo JP. The importance of estradiol for body weight regulation in women. Front Endocrinol. 2022;13:951186. https:\/\/doi.org\/10.3389\/fendo.2022.951186.","journal-title":"Front Endocrinol"},{"key":"1248_CR147","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1067\/mjd.2001.117432","volume":"45","author":"LR Nelson","year":"2001","unstructured":"Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. 2001;45:S116\u201324. https:\/\/doi.org\/10.1067\/mjd.2001.117432.","journal-title":"J Am Acad Dermatol"},{"key":"1248_CR148","volume-title":"Hormone replacement therapy. StatPearls","author":"G Harper-Harrison","year":"2025","unstructured":"Harper-Harrison G, Carlson K, Shanahan MM. Hormone replacement therapy. StatPearls. Treasure Island: StatPearls Publishing; 2025."},{"issue":"11","key":"1248_CR149","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1517\/13543784.16.11.1851","volume":"16","author":"AC Wilson","year":"2007","unstructured":"Wilson AC, Vadakkadath Meethal S, Bowen RL, Atwood CS. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs. 2007;16(11):1851\u201363. https:\/\/doi.org\/10.1517\/13543784.16.11.1851.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"1248_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-023-00713-7","volume":"24","author":"S Yu","year":"2023","unstructured":"Yu S, Zhang Y, Shen C, Shao F. Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2023;24(1):72. https:\/\/doi.org\/10.1186\/s40360-023-00713-7.","journal-title":"BMC Pharmacol Toxicol"},{"key":"1248_CR151","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1345\/aph.10400","volume":"35","author":"SM Fung","year":"2001","unstructured":"Fung SM, Ferrill MJ. Treatment of bulimia nervosa with ondansetron. Ann Pharmacother. 2001;35:1270\u20133. https:\/\/doi.org\/10.1345\/aph.10400.","journal-title":"Ann Pharmacother"},{"issue":"9206","key":"1248_CR152","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S0140-6736(99)09062-5","volume":"355","author":"PL Faris","year":"2000","unstructured":"Faris PL, Kim SW, Meller WH, Goodale RL, Oakman SA, Hofbauer RD, et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet. 2000;355(9206):792\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(99)09062-5.","journal-title":"Lancet"},{"key":"1248_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.764112","volume":"12","author":"A Ragnhildstveit","year":"2021","unstructured":"Ragnhildstveit A, Jackson LK, Cunningham S, Good L, Tanner Q, Roughan M, et al. Case report: unexpected remission from extreme and enduring bulimia nervosa with repeated ketamine assisted psychotherapy. Front Psychiatry. 2021;12:764112. https:\/\/doi.org\/10.3389\/fpsyt.2021.764112.","journal-title":"Front Psychiatry"},{"issue":"3","key":"1248_CR154","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40519-016-0264-x","volume":"21","author":"T \u00c1gh","year":"2016","unstructured":"\u00c1gh T, Kov\u00e1cs G, Supina D, Pawaskar M, Herman BK, Vok\u00f3 Z, et al. A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. Eat Weight Disord Stud Anorex Bulim Obes. 2016;21(3):353\u201364. https:\/\/doi.org\/10.1007\/s40519-016-0264-x.","journal-title":"Eat Weight Disord Stud Anorex Bulim Obes"},{"issue":"1","key":"1248_CR155","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/ajg.2017.441","volume":"113","author":"A Pauwels","year":"2018","unstructured":"Pauwels A, Broers C, Van Houtte B, Rommel N, Vanuytsel T, Tack J. A randomized double-blind, placebo-controlled, cross-over study using baclofen in the treatment of rumination syndrome. Am J Gastroenterol. 2018;113(1):97\u2013104. https:\/\/doi.org\/10.1038\/ajg.2017.441.","journal-title":"Am J Gastroenterol"},{"key":"1248_CR156","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1021\/acschemneuro.0c00254","volume":"11","author":"CN Kent","year":"2020","unstructured":"Kent CN, Park C, Lindsley CW. Classics in chemical neuroscience: baclofen. ACS Chem Neurosci. 2020;11:1740\u201355. https:\/\/doi.org\/10.1021\/acschemneuro.0c00254.","journal-title":"ACS Chem Neurosci"},{"key":"1248_CR157","volume-title":"Baclofen. StatPearls","author":"S Ghanavatian","year":"2025","unstructured":"Ghanavatian S, Derian A. Baclofen. StatPearls. Treasure Island: StatPearls Publishing; 2025."},{"key":"1248_CR158","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/MPG.0000000000001889","volume":"66","author":"R Rosen","year":"2018","unstructured":"Rosen R, Vandenplas Y, Singendonk M, Cabana M, DiLorenzo C, Gottrand F, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:516\u201354. https:\/\/doi.org\/10.1097\/MPG.0000000000001889.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1248_CR159","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/15622975.2023.2179663","volume":"24","author":"H Himmerich","year":"2023","unstructured":"Himmerich H, Lewis YD, Conti C, Mutwalli H, Karwautz A, Sj\u00f6gren JM, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. World J Biol Psychiatry. 2023;24:643\u2013706. https:\/\/doi.org\/10.1080\/15622975.2023.2179663.","journal-title":"World J Biol Psychiatry"},{"issue":"11","key":"1248_CR160","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1002\/eat.24533","volume":"58","author":"L Booij","year":"2025","unstructured":"Booij L, Mizzi E, Ginsberg S, Steiger H. Restrictive and binge-purge OSFED variants: clinical features and comparisons with classical eating disorders. Int J Eat Disord. 2025;58(11):2241\u20135. https:\/\/doi.org\/10.1002\/eat.24533.","journal-title":"Int J Eat Disord"},{"key":"1248_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2023.102267","volume":"101","author":"M Wilkop","year":"2023","unstructured":"Wilkop M, Wade TD, Keegan E, Cohen-Woods S. Impairments among DSM-5 eating disorders: a systematic review and multilevel meta-analysis. Clin Psychol Rev. 2023;101:102267. https:\/\/doi.org\/10.1016\/j.cpr.2023.102267.","journal-title":"Clin Psychol Rev"},{"issue":"2","key":"1248_CR162","doi-asserted-by":"publisher","DOI":"10.1002\/jcv2.12160","volume":"3","author":"T Archibald","year":"2023","unstructured":"Archibald T, Bryant\u2010Waugh R. Current evidence for avoidant restrictive food intake disorder: implications for clinical practice and future directions. JCPP Adv. 2023;3(2):e12160. https:\/\/doi.org\/10.1002\/jcv2.12160.","journal-title":"JCPP Adv"},{"key":"1248_CR163","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11920-017-0795-5","volume":"19","author":"JJ Thomas","year":"2017","unstructured":"Thomas JJ, Lawson EA, Micali N, Misra M, Deckersbach T, Eddy KT. Avoidant\/restrictive food intake disorder: a three-dimensional model of neurobiology with implications for etiology and treatment. Curr Psychiatry Rep. 2017;19:54. https:\/\/doi.org\/10.1007\/s11920-017-0795-5.","journal-title":"Curr Psychiatry Rep"},{"key":"1248_CR164","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40337-024-01021-z","volume":"12","author":"NKO Fonseca","year":"2024","unstructured":"Fonseca NKO, Curtarelli VD, Bertoletti J, Azevedo K, Cardinal TM, Moreira JD, et al. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. J Eat Disord. 2024;12:74. https:\/\/doi.org\/10.1186\/s40337-024-01021-z.","journal-title":"J Eat Disord"},{"issue":"3","key":"1248_CR165","doi-asserted-by":"publisher","first-page":"127","DOI":"10.9740\/mhc.2018.05.127","volume":"8","author":"M Marvanova","year":"2018","unstructured":"Marvanova M, Gramith K. Role of antidepressants in the treatment of adults with anorexia nervosa. Ment Health Clin. 2018;8(3):127\u201337. https:\/\/doi.org\/10.9740\/mhc.2018.05.127.","journal-title":"Ment Health Clin"},{"key":"1248_CR166","doi-asserted-by":"publisher","first-page":"562","DOI":"10.14309\/ajg.0000000000000060","volume":"114","author":"HB Murray","year":"2019","unstructured":"Murray HB, Juarascio AS, Di Lorenzo C, Drossman DA, Thomas JJ. Diagnosis and treatment of rumination syndrome: a critical review. Am J Gastroenterol. 2019;114:562\u201378. https:\/\/doi.org\/10.14309\/ajg.0000000000000060.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1248_CR167","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1053\/j.gastro.2021.11.008","volume":"162","author":"A Josefsson","year":"2022","unstructured":"Josefsson A, Hreinsson JP, Simr\u00e9n M, Tack J, Bangdiwala SI, Sperber AD, et al. Global prevalence and impact of rumination syndrome. Gastroenterology. 2022;162(3):731-742.e9. https:\/\/doi.org\/10.1053\/j.gastro.2021.11.008.","journal-title":"Gastroenterology"},{"issue":"3","key":"1248_CR168","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/wps.20465","volume":"16","author":"SB Murray","year":"2017","unstructured":"Murray SB, Pila E, Griffiths S, Le Grange D. When illness severity and research dollars do not align: are we overlooking eating disorders? World Psychiatry. 2017;16(3):321\u2013321. https:\/\/doi.org\/10.1002\/wps.20465.","journal-title":"World Psychiatry"},{"issue":"4","key":"1248_CR169","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5214\/ans.0972.7531.200409","volume":"20","author":"AA Rikani","year":"2013","unstructured":"Rikani AA, Choudhry Z, Choudhry AM, Ikram H, Asghar MW, Kajal D, et al. A critique of the literature on etiology of eating disorders. Ann Neurosci. 2013;20(4):157\u201361. https:\/\/doi.org\/10.5214\/ans.0972.7531.200409.","journal-title":"Ann Neurosci"},{"issue":"10","key":"1248_CR170","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-013-0396-x","volume":"15","author":"GKW Frank","year":"2013","unstructured":"Frank GKW. Altered brain reward circuits in eating disorders: chicken or egg? Curr Psychiatry Rep. 2013;15(10):396. https:\/\/doi.org\/10.1007\/s11920-013-0396-x.","journal-title":"Curr Psychiatry Rep"},{"issue":"8","key":"1248_CR171","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/eat.24203","volume":"57","author":"VHI Cheung","year":"2024","unstructured":"Cheung VHI, Christie LJ, Maister T, Higgins D, Williams D, Woods N, et al. Identifying potential cases of eating disorders in an acute medical hospital. Int J Eat Disord. 2024;57(8):1707\u201315. https:\/\/doi.org\/10.1002\/eat.24203.","journal-title":"Int J Eat Disord"},{"key":"1248_CR172","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1177\/0004867421998752","volume":"55","author":"L Ivancic","year":"2021","unstructured":"Ivancic L, Maguire S, Miskovic-Wheatley J, Harrison C, Nassar N. Prevalence and management of people with eating disorders presenting to primary care: a national study. Aust N Z J Psychiatry. 2021;55:1089\u2013100. https:\/\/doi.org\/10.1177\/0004867421998752.","journal-title":"Aust N Z J Psychiatry"},{"key":"1248_CR173","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.maturitas.2013.04.014","volume":"75","author":"B Meczekalski","year":"2013","unstructured":"Meczekalski B, Podfigurna-Stopa A, Katulski K. Long-term consequences of anorexia nervosa. Maturitas. 2013;75:215\u201320. https:\/\/doi.org\/10.1016\/j.maturitas.2013.04.014.","journal-title":"Maturitas"},{"key":"1248_CR174","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s40337-024-01174-x","volume":"12","author":"TR Brown","year":"2024","unstructured":"Brown TR, Jansen MO, Hirsch D, Amir H, Duncan AE, Nicol GE. Hiding in plain sight: eating disorders in diverse populations - a case for comprehensive medical education. J Eat Disord. 2024;12:216. https:\/\/doi.org\/10.1186\/s40337-024-01174-x.","journal-title":"J Eat Disord"},{"key":"1248_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.820043","volume":"13","author":"G Halbeisen","year":"2022","unstructured":"Halbeisen G, Brandt G, Paslakis G. A plea for diversity in eating disorders research. Front Psychiatry. 2022;13:820043. https:\/\/doi.org\/10.3389\/fpsyt.2022.820043.","journal-title":"Front Psychiatry"},{"issue":"4","key":"1248_CR176","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/cts.12635","volume":"12","author":"D Chiodin","year":"2019","unstructured":"Chiodin D, Cox EM, Edmund AV, Kratz E, Lockwood SH. Regulatory affairs 101: introduction to investigational new drug applications and clinical trial applications. Clin Transl Sci. 2019;12(4):334\u201342. https:\/\/doi.org\/10.1111\/cts.12635.","journal-title":"Clin Transl Sci"},{"key":"1248_CR177","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00213-024-06722-6","volume":"242","author":"BS Barnett","year":"2025","unstructured":"Barnett BS, Vest MF, Delatte MS, King IF, Mauney EE, Coulson AJ, et al. Practical considerations in the establishment of psychedelic research programs. Psychopharmacology. 2025;242:27\u201343. https:\/\/doi.org\/10.1007\/s00213-024-06722-6.","journal-title":"Psychopharmacology"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01248-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01248-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01248-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:59:08Z","timestamp":1769677148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01248-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":177,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01248-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no potential competing interests with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Waguih William IsHak, Drew Hirsch, Jace Reed, and Rebecca Hedrick contributed to the conceptualization and methodology of the article. The literature search and formal analysis were performed by Drew Hirsch, Jace Reed, Aasim Naqvi, Ashley Ngor, Lauren Dugan, Kelly Costa, Rolando Sceptre Ganasi, and Kyla Truman. The first draft of the manuscript was written by Drew Hirsch, Waguih William IsHak, Jace Reed, and Rolando Sceptre Ganasi. All authors critically edited and revised the work. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}